Odyssey Therapeutics, Inc. ODTX
- Market cap
- $957.8M
- P/E
- 0.0×
Follow ODTX
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
Low Price | ||
| — | — | — | — | — | — | — | — | — | — | High Price | |||
| — | — | — | — | — | — | — | — | — | 100 |
Employees
|
|||
| — | — | — | — | — | — | — | — | — | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | — | — | EBT | |||
| — | — | — | — | — | — | — | — | — | — | EBT Margin | |||
| — | — | — | — | — | — | — | — | — | 0 |
Net Income
|
|||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Earnings/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Cash Flow/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Capex/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Free CF/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Book Value/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Shares | |||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | — | — | Op' Cash Flow | |||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | — | — | FCF | |||
| — | — | — | — | — | — | — | — | — | — | Working Cap' | |||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | — | — | Net Debt | |||
| — | — | — | — | — | — | — | — | — | — | Sh' Equity | |||
| — | — | — | — | — | — | — | — | — | — | ROA | |||
| — | — | — | — | — | — | — | — | — | — | ROIC | |||
| — | — | — | — | — | — | — | — | — | — | ROE | |||
Odyssey Therapeutics, Inc. (ODTX) Latest News
13 Sep
Odyssey Therapeutics (ODTX) secured two additional years of operational runway while expanding its portfolio of clinical trials. Extended cash runway combined with rising trial activity signals major strategic progress that can reshape company trajectory and investor outlook.
10 Aug
Odyssey Therapeutics (ODTX) appears fully valued following its earnings release and Evotec deal. Earnings and Evotec deal draw attention to valuation with only moderate effects on operations and positioning.
7 Aug
Evotec and Odyssey Therapeutics, Inc. enter collaboration focused on AI-enabled R&D. AI collaboration with Evotec constitutes major strategic move that can significantly boost Odyssey drug discovery capabilities and investor sentiment.
6 Aug
Evotec partners with Odyssey Therapeutics on AI-enabled R&D collaboration focused on autoimmune and inflammatory diseases. Strategic AI collaboration directly strengthens Odyssey's drug discovery capabilities and pipeline in core disease areas.
4 Aug
Odyssey Therapeutics reported second quarter 2026 financial results and issued a corporate update. Quarterly results and updates can shift near-term sentiment but rarely redefine long-term trajectory.
17 Jun
Odyssey Therapeutics reported first quarter 2026 financial results and issued a corporate update. Standard quarterly results release with corporate update can moderately shift near-term investor views and valuation.
15 May
Odyssey Therapeutics pulled back from an IPO last year and now carries a valuation near $1 billion. Near-$1B valuation marks major private funding milestone that strengthens capital access and strategic options.
7 May
Odyssey Therapeutics priced its upsized initial public offering. Upsized IPO delivers major capital infusion that alters funding trajectory and investor access.